Skip to main content
Clinical Trials/NCT03427463
NCT03427463CompletedEarly Phase 1

Comparison of 0.1 and 0.05mg Intrathecal Morphine When Administered With a Multimodal Pain Regimen for Post-cesarean Analgesia

Medical University of South Carolina1 site in 1 country229 target enrollmentStarted: January 16, 2018Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Early Phase 1
Status
Completed
Enrollment
229
Locations
1
Primary Endpoint
Time to First Narcotic Rescue Dose in the First 24 Hours Post-cesarean Delivery.

Study Overview

Brief Summary

The purpose of this study is to determine the ideal dose of spinal morphine for use in Cesarean section. Spinal anesthesia (single injection in the lower back to numb patients from the waist down) is commonly used in Cesarean section to provide numbness and pain relief during the surgery, and adding morphine to the spinal anesthetic provides long lasting pain relief for up to 24 hours after surgery. The ideal dose of spinal morphine, when given with other types of pain medications such as nonsteroidal anti-inflammatories and acetaminophen, has not been determined. In addition, spinal morphine can have side effects such as nausea and itching, so using a lower dose of morphine may decrease these side effects while providing the same amount of postoperative pain relief. Study participants will be divided into two groups. Group 1 will receive the standard dose of spinal morphine (0.1mg) while Group 2 will receive a lower dose of spinal morphine (0.05mg). Both groups will receive the standard dose of spinal bupivacaine (numbing medication) and spinal fentanyl (short acting pain medication). The additional pain medications (IV Toradol and oral acetaminophen) will be given to both groups after surgery. Pain control and morphine side effects will be compared between the two groups in order to determine the best dose of spinal morphine for cesarean section.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Masking Description

Patients will be blinded

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • any parturient 18 years of age or older
  • undergoing elective cesarean delivery under spinal anesthesia
  • able to consent to the study and participate in the follow-up.

Exclusion Criteria

  • any known allergy to morphine
  • general anesthesia
  • urgent or emergent cases
  • any bleeding diathesis or other coagulopathy
  • known G6PD deficiency
  • any known liver disease
  • known alcohol abuse or dependence
  • HELLP syndrome
  • thrombocytopenia or known platelet dysfunction
  • history or active gastrointestinal bleeding
  • acute kidney injury or chronic renal insufficiency
  • contraindication/refusal to spinal anesthestic
  • chronic pain
  • chronic narcotic use
  • illicit drug use
  • allergy to any study related medications

Arms & Interventions

receiving 0.1 mg IT morphine

Active Comparator

Patients will receive the standard of care dose 0.1 mg of intrathecal morphine

Intervention: receiving 0.1 mg IT morphine (Drug)

recieving 0.05 mg IT morphine

Experimental

Patients will receive 0.05 mg of intrathecal morphine

Intervention: recieving 0.05 mg IT morphine (Drug)

Outcomes

Primary Outcomes

Time to First Narcotic Rescue Dose in the First 24 Hours Post-cesarean Delivery.

Time Frame: 24 hours

This is defined as the number of hours until the first rescue dose of medication was given to participants within the first 24-hours post-op.

Secondary Outcomes

  • Time to First Ambulation After C-section(up to 48 hours)
  • Opioid Medication Given During the Participant's Hospital Stay.(From the time of the procedure through discharge, up to 48 hours.)
  • Subjective Pain Rating Using Visual Analogue Scales (VAS) Ranging From 0-100.(24-hours post operatively and 48-hours post operatively)
  • Presence of Opiate Side Effects (Nausea, Vomiting, and Pruritus)(24 hours post operavtively)
  • Overall Patient Satisfaction With Pain Control(48 hours post-op)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Katherine Hatter, MD

Assistant Professor

Medical University of South Carolina

Study Sites (1)

Loading locations...

Similar Trials